The National Council on Radiation Protection (NCRP)-156 Report proposes seven different biokinetic models for wound cases depending on the physicochemistry of the contaminant. Because the models were heavily based on experimental animal data, the authors of the report encouraged application and validation of the models using bioassay data from actual human exposures. Each of the wound models was applied to three plutonium-contaminated wounds, and the models resulted in a good agreement to only one of the cases. We then applied a simpler biokinetic model structure to the bioassay data and showed that fitting the transfer rates from this model structure yielded better agreement with the data than does the best-fitting NCRP-156 model. Because the biokinetics of radioactive material in each wound is different, it is impractical to propose a discrete set of model parameters to describe the biokinetics of radionuclides in all wounds, and thus each wound should be treated empirically.
INTRODUCTION
Intakes of radioactive materials via wounds, although not as common as other pathways of intake, are a significant contributor to intakes and doses in the nuclear industry. Accidental intakes of actinides via the wound pathway are relatively common in plutonium production and reprocessing facilities (1) (2) (3) (4) (5) (6) (7) (8) (9) , and the pathway typically results in larger intakes and doses than inhalation or ingestion pathways. As such, the retention of actinides in the wound site and their absorption into the blood are of interest to internal dosimetrists.
The biokinetics of radioactive materials deposited in wounds are inherently different from that of ingested, inhaled or injected radioactive materials (10) . Therefore, the National Council on Radiation Protection and Measurements (NCRP), in collaboration with the International Commission on Radiological Protection (ICRP), developed a biokinetic model for the behavior of radioactive materials in wounds (11) . Since the NCRP 156 wound model-which now represents a consensus biokinetic model for the analysis of bioassay data from contaminated wounds-was derived from experimental data on animals, the authors of the report encouraged application of the models to bioassay data from humans (12) . Moreover, the wound model is a relatively recent addition to the family of biokinetic models used for intake and dose estimation, so it is imperative that attempts to validate, improve and revise the wound models be continued.
The objective of this article was to apply the NCRP 156 wound models to the urinary excretion data from three plutonium-contaminated wound cases that occurred at Los Alamos National Laboratory (LANL). In addition, the paper also applies a simplified compartmental wound model structure that is capable of describing the urinary excretion of plutonium irrespective of its initial solubility. DATA LANL has had several wound intakes over a period of several decades of its operation. Of these several wound cases, three were selected for this article based on the following justifications:
(1) The persons had an intake of This ensures that the bioassay data collected after the wound incident can be completely attributed to the wound incident. (3) The persons did not receive any chelation treatment after the intake. Since chelation perturbs the urinary excretion data after an intake for a period of up to several months after the last chelation, the bioassay data from chelated cases could not be used to develop a biokinetic model. (4) The persons did not show any apparent discontinuity in the urinary excretion data. Surgical exploration and excision of contaminated wound tissue is frequently the treatment of choice following a wound incident. Removal of contaminant or the contaminated tissue from the wound site results in a discontinuity in the source-term and hence the bioassay data.
(5) The bioassay data for the case contains at least one urinary excretion data-point collected prior to a week after the wound incident. This was done to ensure that the early behavior of the contaminant is taken into account. (6) The plutonium content in urine was measured using radiochemical alpha spectroscopy (RAS). (7) The cases have been followed for long enough time such that more than 10 (arbitrarily chosen number) bioassay data points are available. (8) Urinary excretion data after a new intake were not analyzed. For example, case 2 had an inhalation intake on 1091 days after the wound incident in consideration. The bioassay data collected after the inhalation incident were not used in this analysis.
The summary of the data used in this analysis is given in Table 1 . Readers interested in independent analysis can obtain the bioassay data for these cases by contacting the corresponding author.
INTERPRETATION OF BIOASSAY DATA USING THE NCRP 156 WOUND MODELS
The wound models described in NCRP Report No. 156 (11) represent a relatively recent addition to the current family of pre-systemic models developed for various forms of intake. The report proposes a multi-compartmental biokinetic model created using the mechanistic framework of biochemical principles. A generic wound model consists of five compartments: soluble; colloidal and intermediate states (CIS); particles, aggregates and bound states (PABS); trapped particles and aggregates (TPA); and fragments. These compartments describe wound-site retention, systemic uptake into the blood and clearance into the lymph nodes for both soluble and insoluble radioactive material. The category 'soluble' is further divided into 'weakly-retained' (WSW), 'moderately retained' (WSM), 'strongly retained' (WSS) and 'avidly retained' (WSA) categories depending on their solubility. Similarly, particulate materials are further grouped into 'colloids' (WCO), 'particles' (WPA) or 'fragment' (WFR) categories based on their physical properties and retention pattern. The transfer of activity between the compartments is described by first-order kinetics, and the transfer rates between the compartments for the default seven categories of radioactive materials are given in the NCRP Report.
To evaluate the urinary excretion data and assess the intake via contaminated wounds, the wound model can be coupled with a plutonium systemic model (11) (12) (13) . The intake can be estimated from the available urinary excretion data using one of the several statistical methods (14, 15) . One commonly used method is the maximum likelihood method, which minimizes chi-square given as follows (16) :
and the estimate of the intake, I, is given as follows:
where M i is the value of the ith measurement, m(t i ) is the intake retention fraction or excretion fraction associated with the ith measurement, and I i is the intake calculated from the ith measurement, and is given as,
. The IDEAS guidelines (16) assume that the uncertainty on a bioassay datum can be described as a lognormal distribution, and the scattering factor, SF, is the exponential of the geometric standard deviation (GSD), S, of the distribution (17) . The above equations incorporate the often crucial lognormal uncertainty (e.g. uncertainties related to excretion time and detection efficiency) associated with the bioassay measurements, however, they have their own limitations. For example, the equations cannot be used to interpret negative bioassay measurements, and are only suitable for precise measurements which are well separated from zero (16, 18, 19) . Nevertheless, these equations are widely used in interpreting bioassay measurements, and are also implemented in internal dosimetry software packages such as Integrated Modules for Bioassay Analysis (IMBA) (20) and Activity and Internal Dose Estimates (AIDE) (21) that are commonly used for official intake and dose calculations. This paper therefore relies on these equations for consistency with the IDEAS guidelines established for harmonization of intake and dose calculation.
Usually in a bioassay measurement, Type A uncertainties (e.g. uncertainties due to counting statistics) are dominated by Type B uncertainties (e.g. uncertainties relating to calibration). Assuming this is the case, the SF or the S can be taken to be constant for the same type of monitoring data (16) . This article uses an S value of 0.5 for the urinary excretion data, which is approximately equal to the value recommended by the IDEAS guidelines (SF of 1.6) for simulated 24-h urine samples (16) . This simplifies equation (2) to:
The urinary excretion fractions, m(t i ), were calculated using the method described by Birchall and James (22) . The calculations specific to wound intakes-which have been described in earlier publications (23, 24) -were coded in Python ® , and verified using the internal dosimetry software package AIDE (21) . Since the actual chemistry and the solubility of the material was unknown, the urinary excretion data from the three cases were analyzed using all seven default NCRP 156 wound models combined with the Leggett's systemic model (25) . The intakes estimated using the maximum likelihood analysis and the resulting χ N / 2 are given in Table 2 . The model is considered to be consistent with the data when χ 2 per data-point is roughly one or less (19, 26) . The intake estimates, as expected, depended significantly on the choice of the wound model used for the analysis. For example, the intakes estimated for case two ranged from 22.11 Bq using the WSM model to 14 150 Bq using the WFR model. However, it is important to take into account the associated χ N / 2 value. For case 2, the best fit (χ = N / 1.01
2 ) was obtained using the WSS model with an intake estimate of 25.62 Bq. Similarly, the best fits were obtained using WSA model for cases 1 and 3 with intake estimations of 42.43 and 35.04 Bq, respectively. For cases 1 and 3, none of the default wound models fit the bioassay data well (i.e. χ > N / 1 2 ).
A SIMPLIFIED BIOKINETIC APPROACH
Prior to the publication of the NCRP 156 Report, wound cases were analyzed using two compartments, one of which feeds the blood at a 'rapid' rate and the other at a slower rate (27) . Sometimes, additional compartments have been used to more appropriately describe the transfer of radioactive materials into the transfer compartment (28) . These approaches, while simple, were just empirical descriptions of the model and lack a complete physiological justification. This article explored the possibility of a physiological biokinetic model structure-simpler than that of the NCRP 156 model-to explain urinary excretion after plutonium-contaminated wound cases. The proposed model structure consists of only three compartments (not including the blood): 'soluble', 'insoluble' and 'lymph nodes', compared to four to five compartments in the NCRP 156 wound models. The structure of the two models are compared in Figure 1 .
The NCRP 156 models assume injection of 100% of the intake activity into either the soluble, CIS, PABS or fragment compartments depending on the solubility and chemistry of the radioactive material in question (Figure 1 ). However, a person may be working with forms of plutonium that cannot be described as purely belonging to one of the seven default NCRP 156 categories. For example, a wound incurred by a plutonium process operator may involve both soluble and insoluble forms of plutonium. In cases where the contaminating material consists of a mixture of different forms of plutonium, a combination of the NCRP 156 default models can be used to explain the bioassay data. This approach is also the method recommended by the IDEAS guidelines (16) . However, combining two or more (up to seven) pre-systemic models with a systemic model results in a severely complicated model structure with a large number of parameters.
In contrast, the method we use here (Figure 1e ) allows fractions of the total intake to be deposited into soluble or insoluble compartments. In addition, the model also allows for the possibility of a fraction of radioactive material being directly injected into the blood. This addition-similar to the approach used by Piechowski et al. (29) -is important to wound modeling because a significant fraction of the radioactive material may directly enter the blood via vascular injury. The LANL Bayesian Markov-Chain Monte Carlo Internal Dosimetry Code also uses injection (i.e. direct input into blood) as one of the model priors for wound modeling, and many times, a significant fraction of the intake could be explained assuming direct injection (30) . Similar to the NCRP 156 model, the transfer of activity between the wound compartments is assumed to follow first-order kinetics. Materials in the 'soluble' compartment may be directly absorbed into the blood, or may become insoluble or sparingly soluble via processes such as the formation of colloids, hydroxides, precipitates or oxidation of plutonium (11) . A fraction of the material deposited in the insoluble compartment may undergo dissolution and transfer back into the 'soluble' compartment, albeit very slowly. Similar to several historical approaches to wound modeling (29, 31) , a fraction of material in the insoluble compartment is assumed to be transported to blood via the lymphatic system. The clearance to lymph nodes is more significant for radioactive materials in insoluble form (e.g. particles or aggregates) than for those in soluble form (11) . The 'soluble' compartment in the proposed model represents all forms of soluble materials-weakly, moderately, strongly or avidly retained. Similarly, the 'insoluble' compartment in the model is meant to represent colloidal, bound, particulate or fragmental forms of plutonium, with the distinction between the forms to be made using the rate of transfer of materials to the lymph nodes or to the soluble compartment. For example, particulate plutonium, due to its insolubility and potential for foreign-body encapsulation, would have a longer retention in the 'insoluble' compartment (i.e. smaller transfer rate) compared to colloidal plutonium. The lymph nodes together with the 'insoluble' compartment represent long-term retention at the wound-site.
The wound model can be combined with a systemic model via blood, which is a clearance compartment in the wound model and a transfer compartment in the systemic model (Figure 2) . To derive the models applicable to the wound cases discussed in this paper, the transfer parameters were sampled from a lognormal distribution given in Table 3 . The medians of the sampling regime were based on the judgment of values of transfer rates between the compartments given in Figure 2 . Combined implementation of the wound model with Leggett's systemic model (25) for plutonium and the ICRP alimentary tract model (32) . a (Minimum, maximum) for a loguniform distribution; (median, GSD) for a lognormal distribution.
the NCRP 156 report (11) , and a GSD of three provides a wide range to sample the parameters from. The intake parameters, i.e. the initialization of soluble, insoluble, and blood compartments, were sampled from a loguniform distribution ranging from 0.01 to 100 Bq. Because intake is the sum of the initialization of these three compartments, this allows the estimates of intake to be from 0.03 to 300 Bq.
Using random sampling from the given range of the parameters (Table 3), 10 6 'hypothetical models' were created for each case. For each of these models, the agreement between the predictions of the model with the measured urinary excretion data was evaluated based on the value of chi-square per data-point.
were obtained for all cases. The model parameters that produced the minimum χ N / 2 for each case are given in Table 4 .
DISCUSSION
The intakes estimated and the associated goodness of fit using the new wound model structure have been compared with those obtained using the default NCRP 156 wound models ( Table 5 ). The intake estimated for case two using the new approach was within 6% of that estimated using the default NCRP 156 wound models, and the fit of the data is much improved. For cases 1 and 3, the intakes estimated using the new approach are significantly different (11 and 60%) than those estimated using the NCRP 156 wound models. It is important to note that the estimates obtained using the default NCRP 156 wound models for cases 1 and 3 are not considered 'reliable' because of their relatively high χ N /
2
. Because an improper assumption about the default retention class of NCRP 156 wound model may lead to estimates of intake several orders of magnitude different from each other (Table 2) , intake estimates obtained using maximum likelihood analysis of bioassay data should always be viewed in conjunction with the associated fit. The fit of the urinary excretion data for all three cases using both methods have been compared in Figure 3 .
A review (24) of applications of the NCRP 156 wound models to human data shows that adjustments to some (8, 33) or all (34, 35) model parameters have been necessary to explain the bioassay data and/or the wound-retention data in humans. Moreover, because plutonium of several different solubilities and chemistries are expected at a workplace, combinations of two or more wound models were necessary in some cases. In other cases (23) , such combination of default wound models was insufficient to describe the bioassay data. Our approach dealt with this problem by allowing different forms of plutonium (soluble or insoluble) to be deposited simultaneously in different wound compartments, and varying the transfer rates between the wound compartments as applicable.
It should be noted that the wound models in NCRP 156 report were parameterized using the wound retention data in experimental animals, whereas the model parameters in this paper were derived from urinary excretion data. It is acknowledged that combining urinary excretion data with the wound retention data would have been more appropriate, however, given the historic nature of the wound cases discussed in this paper, no data on wound counts could be retrieved. Wound models obtained using the urinary excretion data are nevertheless useful in internal dosimetry, because most facilities obtain official estimates of intakes and doses for plutonium based on the urinary excretion data alone. However, it is recommended that data on wound retention, when available, be used along with the urinary excretion data for modeling wound intakes because such data add crucial information on the type(s) of the material involved in a wound incident (23) . It is impractical to propose a single set of model parameters to describe the biokinetics of radionuclides in all wounds, because a contaminated wound presents a large number of different characteristics. For example, the biokinetics of a radioactive material in a wound depend on the nature of the contaminant (i.e. solubility, physicochemistry, particle size and mass), the nature of the wound (i.e. abrasion or a puncture, anatomical location) and the pathophysiological response of the tissue (i.e. fibrosis, encapsulation) (10, 11, 24, 29, 36) . This also explains the differences in the values of the transfer rates, even among a small number of cases that occurred within the same facility (Table 4) .
CONCLUSION
Our objective-to propose a simple schema for the transfer of radionuclides within and from the wound site using physiological justifications-was successfully achieved. Moreover, we showed that fitting the transfer rates from this simplified model structure yields better agreement with the bioassay data from a range of wound cases than does the best-fitting NCRP 156 wound model. While default recommendations for the biokinetics of wounds can be used as a starting point, it is important to understand that each wound is different and thus should be treated empirically as such.
It is important to note that a majority of the wound cases encountered in a plutonium production or reprocessing facility involves surgical excision and/or administration of chelation therapy. Surgical removal of contaminant or the contaminant tissue causes (partial) removal of the source-term thus decreasing the absorption of plutonium into the blood. Similarly, administration of chelating agents like DTPA decreases the retention of plutonium in the body by increasing the urinary excretion. The model structure developed above is applicable to the wound cases that are not confounded by the medical treatments. The biokinetic behavior of Pu-DTPA is and those of the models described in this article.
